| 1 |
34475048 | P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma. | 2021 Sep |
9 |
| 2 |
31268155 | Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment. | 2019 Aug |
2 |
| 3 |
29435010 | Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis. | 2018 Mar |
1 |
| 4 |
30205729 | HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. | 2018 |
9 |
| 5 |
28870911 | Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways. | 2017 Sep |
2 |
| 6 |
27288242 | The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries. | 2016 Sep |
1 |
| 7 |
27485825 | Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma. | 2016 Sep |
1 |
| 8 |
23497256 | Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. | 2013 Mar 5 |
1 |
| 9 |
23578198 | Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. | 2013 Aug |
3 |
| 10 |
22314934 | Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. | 2012 May |
2 |
| 11 |
22662219 | p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. | 2012 |
1 |